Cargando…
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
Cancer cells often depend on multiple pathways for their growth and survival, resulting in therapeutic resistance and the limited effectiveness of treatments. Combination therapy has emerged as a favorable approach to enhance treatment efficacy and minimize acquired resistance and harmful side effec...
Autor principal: | Alaseem, Ali M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561124/ https://www.ncbi.nlm.nih.gov/pubmed/37818252 http://dx.doi.org/10.1016/j.jsps.2023.101790 |
Ejemplares similares
-
MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation
por: Pellot Ortiz, Karolina I., et al.
Publicado: (2023) -
Mouse models of Mdm2 and Mdm4 and their clinical implications
por: Xiong, Shunbin
Publicado: (2013) -
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015) -
MDM2 Overexpression Modulates the Angiogenesis-Related Gene Expression Profile of Prostate Cancer Cells
por: Venkatesan, Thiagarajan, et al.
Publicado: (2018) -
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022)